CSL’s collapse deepens. Why this ASX giant can’t find a floor

CSL Ltd (ASX: CSL) shares are breaking down again on Wednesday, with selling pressure pushing the stock to levels not seen in nearly a decade.

At the time of writing, the CSL share price is down 5.10% to $130.02.

Earlier in afternoon trade, the stock fell as low as $128.675, marking a 9-year low and extending one of the steepest declines seen in a blue-chip behemoth in recent years.

It also comes during a weaker session for the broader market.

The S&P/ASX 200 Index (ASX: XJO) is down 1.07% to 8,853 points, with healthcare among the sectors under pressure.

Here’s what appears to be driving the latest leg lower.

A key demand driver just took a hit

One of the key triggers appears to be fresh policy changes in the United States.

According to The Australian, the US military has scrapped its annual flu shot requirement for service members. While vaccinations remain available, the removal of a broad mandate changes the demand outlook.

CSL generates a significant portion of its revenue from the US, with its influenza vaccines forming part of that exposure.

A policy shift like this feeds directly into investor concerns around vaccine volumes. Lower uptake could weigh on future sales, particularly in segments where demand was previously supported by mandates.

The selling didn’t start today

The latest drop adds to a trend that has been building for some time.

CSL has been working through a slower growth phase, with expectations pulled back over the past 18 months. Earlier updates pointed to softer earnings momentum, driven by pressure in vaccines and margins.

At the same time, healthcare stocks have fallen out of favour in 2026. Capital has moved into other parts of the market, leaving former high-multiple names exposed.

Recent developments across the sector have added to the pressure. Cochlear Ltd (ASX: COH)’s profit warning has weighed on sentiment and reinforced concerns around earnings visibility.

That backdrop has left CSL more vulnerable to negative news.

A blue-chip reset that’s too hard to ignore

The scale of the decline stands out given CSL’s history.

For years, it was viewed as one of the ASX’s most dependable growth companies. Strong earnings expansion and global leadership in plasma therapies supported a premium valuation.

That premium has now been stripped out.

The share price is trading well below prior highs, and valuation multiples have compressed alongside slower growth expectations.

The core business remains solid, particularly in plasma-derived therapies where demand continues to build over time. But the market is placing more weight on near-term earnings than long-term positioning.

Foolish Takeaway

CSL’s slide to a 9-year low reflects a combination of shifting demand expectations and broader sector pressure.

The removal of a US flu shot mandate has added another layer of uncertainty at a time when growth is already under scrutiny.

With sentiment toward healthcare stocks still fragile, the shares have struggled to find support.

The next phase will depend on whether earnings can stabilise and rebuild confidence.

The post CSL’s collapse deepens. Why this ASX giant can’t find a floor appeared first on The Motley Fool Australia.

More reading

• Prediction: CSL shares could surpass $265 in 2026
• Are ASX healthcare shares the next to rally?
• 5 oversold ASX shares to buy before the end of April
• 2 ASX healthcare shares I think can beat the market
• How much could a $10,000 investment in these undervalued ASX 200 shares be worth in a year?

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Cochlear. The Motley Fool Australia has recommended CSL and Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.